CoChat

Immunogenicity of pembrolizumab in patients with advanced tumors

Open access
van Vugt, Marianne J. H., Stone, Julie A., De Greef, “Rik” H. J. M. M., Snyder, Ellen S., Lipka, Leslie, Turner, David C., Chain, Anne, Lala, Mallika, Li, Mengyao, Robey, Seth H., Kondic, Anna G., De Alwis, Dinesh, Mayawala, Kapil, Jain, Lokesh, Freshwater, Tomoko · 2019 · Journal for ImmunoTherapy of Cancer

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Pembrolizumab is a potent, humanized, monoclonal anti-programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug antibodies (ADAs), which may alter drug clearance and neutralize target binding, potentially reducing drug efficacy; such immunogenicity may also result in infusion reactions, anaphylaxis, and immune complex disorders. Pembrolizumab immunogenicity and its impact on exposure, safety, and efficacy was assessed in this study. PATIENTS AND METHODS: Pembrolizumab immunogenicity was assessed in 3655 patients with advanced or metastatic cancer treated in 12 clinical studies. Patients with melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, urothelial cancer, and Hodgkin lymphoma were treated with pembrolizumab at 2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 200 mg every 3 weeks. An additional study involving 496 patients with stage III melanoma treated with 200 mg adjuvant pembrolizumab every 3 weeks after complete resection was analyzed separately. RESULTS: Of 3655 patients, 2000 were evaluable for immunogenicity analysis, 36 (1.8%) were treatment-emergent (TE) ADA-positive; 9 (0.5%) of these TE-positive patients had antibodies with neutralizing capacity. The presence of pembrolizumab-specific ADAs did not impact pembrolizumab exposure, nor did pembrolizumab immunogenicity affect the incidence of drug-related adverse events (AEs) or infusion-related reactions. There was no clear relationship between the presence of pembrolizumab-specific ADAs and changes in tumor size across treatment regimens. Of the 496 patients treated with pembrolizumab as adjuvant therapy, 495 were evaluable, 17 (3.4%) were TE ADA-positive; none had neutralizing antibodies. CONCLUSIONS: The incidence of TE (neutralizing positive) ADAs against pembrolizumab was low in patients with advanced tumors. Furthermore, immunogenicity did not appear to have any clinically relevant effects on the exposure, safety, or efficacy of pembrolizumab. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01295827 (February 15, 2011), NCT01704287 (October 11, 2012), NCT01866319 (May 31, 2013), NCT01905657 (July 23, 2013), NCT02142738 (May 20, 2014), NCT01848834 (May 8, 2013), NCT02255097 (October 2, 2014), NCT02460198 (June 2, 2015), NCT01953692 (October 1, 2013), NCT02453594 (May 25, 2015), NCT02256436 (October 3, 2014), NCT02335424 (January 9, 2015), NCT02362594 (February 13, 2015).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-019-0663-4

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pembrolizumab ADA patient analysis. ADA, antidrug antibody; NAb, neutralizing antibody; non-TE, non–treatment-emergent; TE, treatment-emergent
Fig. 1 Pembrolizumab ADA patient analysis. ADA, antidrug antibody; NAb, neutralizing antibody; non-TE, non–treatment-emergent; TE, treatment-emergentCC BY · PubMed Central
Fig. 2 Change in tumor size of evaluable patients treated with pembrolizumab in the non-adjuvant setting at doses of 200 mg Q3W (N = 713) (a), 2 mg/kg Q3W (N = 522) (b), 10 mg/kg Q3W (N = 399) (c), and 10 mg/kg Q2W (N = 95) (d). Figure includes tumor size change for all ADA evaluable patients. ADA, antidrug antibody; NAb, neutralizing antibody; non-TE, non–treatment-emergent ADA positive; Q2W, every 2 weeks; Q3W, every 3 weeks; TE, treatment-emergent ADA positive
Fig. 2 Change in tumor size of evaluable patients treated with pembrolizumab in the non-adjuvant setting at doses of 200 mg Q3W (N = 713) (a), 2 mg/kg Q3W (N = 522) (b), 10 mg/kg Q3W (N = 399) (c), and 10 mg/kg Q2W (N = 95) (d). Figure includes tumor size change for all ADA evaluable patients. ADA, antidrug antibody; NAb, neutralizing antibody; non-TE, non–treatment-emergent ADA positive; Q2W, every 2 weeks; Q3W, every 3 weeks; TE, treatment-emergent ADA positiveCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 57

Metadata

Authors
van Vugt, M. J. H., Stone, J. A., De Greef, “. H. J. M. M., Snyder, E. S., Lipka, L., Turner, D. C., Chain, A., Lala, M., Li, M., Robey, S. H., Kondic, A. G., De Alwis, D., Mayawala, K., Jain, L., & Freshwater, T.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Certara (United States) (US)
Corresponding author
Freshwater, Tomoko
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2019-08-08
Volume
7
Issue
1
Pages
212-212
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2967423315
Cited by
57
References
17
Citations by year
2026: 5 · 2025: 10 · 2024: 13 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 4
FWCI
2.30
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (NA)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
pembrolizumab, immunogenicity, antidrug antibodies, PD-1 inhibitors, neutralizing antibodies, drug exposure, infusion reactions, adjuvant therapy, melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, Hodgkin's disease, colorectal cancer, drug safety and efficacy
MeSH terms
Antineoplastic Agents, Immunological, Female, Humans, Male, Neoplasms, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenicity of pembrolizumab in patients with advanced tumors. https://app.cochat.ai/papers/10.1186/s40425-019-0663-4
The paper
van Vugt, M. J. H., Stone, J. A., De Greef, “. H. J. M. M., Snyder, E. S., Lipka, L., Turner, D. C., Chain, A., Lala, M., Li, M., Robey, S. H., Kondic, A. G., De Alwis, D., Mayawala, K., Jain, L., & Freshwater, T. (2019). Immunogenicity of pembrolizumab in patients with advanced tumors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0663-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.